Ultragenyx Pharmaceutical Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
RARE$16.14-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In millions, except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenues: | ||||
| Product sales | $105 | $95 | $306 | $267 |
| Royalty revenue | 68 | 65 | 217 | 199 |
| Total revenues | 173 | 160 | 523 | 466 |
| Operating expenses: | ||||
| Cost of sales | 32 | 28 | 96 | 80 |
| Research and development | 154 | 216 | 508 | 547 |
| Selling, general and administrative | 97 | 87 | 273 | 261 |
| Total operating expenses | 283 | 331 | 877 | 888 |
| Loss from operations | (110) | (171) | (354) | (422) |
| Interest income | 3 | 6 | 14 | 19 |
| Non-cash interest expense on liabilities for sales of future royalties | (20) | (14) | (63) | (42) |
| Other income | — | — | 1 | 2 |
| Loss before income taxes | (127) | (179) | (402) | (443) |
| Benefit from (provision for) income taxes | 9 | (1) | 7 | (3) |
| Net loss | $(118) | $(180) | $(395) | $(446) |
| Net loss per share, basic and diluted | $(1.16) | $(1.81) | $(3.89) | $(4.55) |
| Shares used in computing net loss per share, basic and diluted | 102.1 | 99.8 | 101.6 | 98.2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.